

S3 Table. The association between patients' characteristics and first-line EGFR-TKI treatment

Characteristic	First-line EGFR-TKI			p-value ^{a)}
	Gefitinib	Erlotinib	Afatinib	
Age (yr)				
≤ 60	42 (44.7)	52 (53.1)	9 (69.2)	0.186
> 60	52 (55.3)	46 (46.9)	4 (30.8)	
Sex				
Male	25 (26.6)	45 (45.9)	6 (46.2)	0.015
Female	69 (73.4)	53 (54.1)	7 (53.8)	
Smoking status				
Non-smokers	77 (81.9)	75 (76.5)	10 (76.9)	0.676
Current/Former-smokers	17 (18.1)	23 (23.4)	3 (23.1)	
Baseline <i>EGFR</i> mutation status				
19Del	53 (56.4)	51 (52.0)	7 (53.8)	0.117
L858R	37 (39.4)	43 (43.9)	3 (23.1)	
Others	4 (4.2)	4 (4.1)	3 (23.1)	
Best response of first line TKI				
Stable disease	13 (13.8)	15 (15.3)	1 (7.7)	0.856
Partial response	81 (86.2)	83 (84.7)	12 (92.3)	
PFS of first-line TKI				
≤ 11 mo	44 (46.8)	55 (56.1)	8 (61.5)	0.353
> 11 mo	50 (53.2)	43 (43.9)	5 (38.5)	
Re-biopsy site				
Primary	26 (27.7)	38 (38.8)	4 (30.8)	0.259
Metastases	68 (72.3)	60 (61.2)	9 (69.2)	

EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; PFS, progression-free survival. ^{a)}By Fisher exact test.